KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Revenue (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Revenue for 4 consecutive years, with $9.2 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Revenue fell 57.4% year-over-year to $9.2 million, compared with a TTM value of $9.2 million through Sep 2024, down 81.78%, and an annual FY2024 reading of $28.8 million, down 24.17% over the prior year.
  • Revenue was $9.2 million for Q4 2023 at AbCellera Biologics, up from $6.6 million in the prior quarter.
  • Across five years, Revenue topped out at $316.6 million in Q1 2022 and bottomed at $4.7 million in Q1 2020.
  • Average Revenue over 4 years is $70.7 million, with a median of $16.9 million recorded in 2022.
  • The sharpest move saw Revenue skyrocketed 4253.47% in 2021, then crashed 96.15% in 2023.
  • Year by year, Revenue stood at $207.9 million in 2020, then crashed by 32.98% to $139.3 million in 2021, then tumbled by 84.54% to $21.5 million in 2022, then plummeted by 57.4% to $9.2 million in 2023.
  • Business Quant data shows Revenue for ABCL at $9.2 million in Q4 2023, $6.6 million in Q3 2023, and $10.1 million in Q2 2023.